Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Gadoxetic Acid' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Gadoxetic Acid' found in 1 term [] and 5 definitions []
1 - 5 (of 6)     next
Result Pages : [1]  [2]
Searchterm 'Gadoxetic Acid' was also found in the following service: 
spacer
News  (1)  
 
Gadoxetic AcidInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-EOB-DTPA, generic name: Gadoxetic acid, chemical compound: Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid
Primovist™ (formerly Eovist®) is a nonionic water-soluble liver tissue-specific MRI contrast agent with positive enhancement. The agent allows detection and differentiation of hepatic tumors due to specific uptake by healthy liver tissue, but not by tumors in the affected organ. Gd-EOB-DTPA has hepatocyte-specific properties, but provides earlier perfusion information acquired within first ten minutes. Hepatocyte uptake generally occurs beyond 10 minutes.
spacer
 
• Share the entry 'Gadoxetic Acid':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
Added Value of Gadoxetic Acid-enhanced Liver Magnetic Resonance Imaging for Diagnosis of Small (10-19 mm) or Atypical Hepatic Nodules at Contrast-enhanced Computed Tomography: A Prospective Study
Tuesday, 7 February 2017   by www.clinicaltrials.gov    
  News & More:
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
Thursday, 11 March 2021   by www.docwirenews.com    
New MRI Liver Contrast Medium
Wednesday, 13 October 2004   by www.hospimedica.com    
MRI Resources 
Process Analysis - Sequences - Supplies - Lung Imaging - Research Labs - Contrast Enhanced MRI
 
Eovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Eovist® (other brand name Primovist™) is a organ specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans. Excretion of Gd-EOB-DTPA in the bile may also permit visualization of both the gall bladder and the bile ducts.
Eovist® brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic and accumulation phase imaging can also be performed after bolus injection of Eovist®. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma at 10 to 20 minutes after injection. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Drug Development and Approval Process USA, Contrast Medium, Hepatobiliary Contrast Agents, Tumor Specific Agents and Molecular Imaging.
Drug Information and Specification
NAME OF COMPOUND
Gadoxetic acid disodium, Gd-EOB-DTPA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Short T1-relaxation time
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
884 mosm/kgH2O
CONCENTRATION
0.25 mol/L
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
spacer

• View the DATABASE results for 'Eovist®' (4).Open this link in a new window

 
Further Reading:
  Basics:
HIGHLIGHTS OF PRESCRIBING INFORMATION
2008   by berlex.bayerhealthcare.com    
MRI Resources 
Jobs - Brain MRI - Implant and Prosthesis - MRI Physics - RIS - Corporations
 
Intracellular Contrast AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Contrast agent with a preferential intracellular distribution.
Intracellular agents (such as manganese derivatives and ultrasmall superparamagnetic iron oxide), exhibit a flow- and metabolism-dependent uptake. These properties may allow delayed imaging, similar to isotopic methods.
Phospholipid liposomes are rapidly sequestered by the cells in the reticuloendothelial system (RES), primarily in the liver. For imaging of the liver, liposomes may be labeled with MR contrast medium, both positive (T1-shortening) paramagnetic media, and negative (T2-shortening) superparamagnetic media.
Several other nonliposome MR contrast media are also taken up by the RES, e.g.:
Other MR contrast agents accumulate selectively in the hepatocytes, e.g.:
gadoxetic acid (Gd-EOB-DTPA)
spacer

• View the DATABASE results for 'Intracellular Contrast Agents' (3).Open this link in a new window

 
Further Reading:
  News & More:
Manganese enhanced MRI provides more accurate details of heart function after a heart attack
Tuesday, 11 May 2021   by www.news-medical.net    
Searchterm 'Gadoxetic Acid' was also found in the following service: 
spacer
News  (1)  
 
Magnetic Resonance CholangiopancreaticographyMRI Resource Directory:
 - MRCP -
 
(MRCP) This MR imaging technique takes advantage of the high signal intensity of body fluids and acquires heavy T2 weighted images of the gall bladder, the pancreas and parts of the liver. Due to the T2 weighting, the liver and other solid parenchyma are signal suppressed and only fluid-filled structures in addition to the gall bladder, the bile and pancreatic ducts retain important signal intensity. Hepatobiliary contrast agents (e.g. Gadoxetic Acid, CMC 001) can be useful for enhancement of the bile ducts and better imaging of the biliary tract.
A 2D cholangiogram, often only one thick slice (a volume with a thickness of 4 - 8 cm, mostly coronal planned) or 5 - 6 radial placed slices, shows a view like single slices. If a 3D acquisition is used, the postprocessing function maximum intensity projection (MIP) can show reconstructions from multiple sides.
Radiology-tip.comradBiliary Contrast Agents
spacer
Medical-Ultrasound-Imaging.comGallbladder Ultrasound
spacer

• View the DATABASE results for 'Magnetic Resonance Cholangiopancreaticography' (3).Open this link in a new window

 
Further Reading:
  News & More:
Perspectum and Nuance Collaborate to Scale Access to AI-Enabled Integrated Digital Care Platforms to Improve Patient Care for Metabolic Disease
Friday, 9 December 2022   by www.itnonline.com    
MRI Resources 
Manufacturers - Safety Training - Cochlear Implant - Shoulder MRI - MR Myelography - MRI Technician and Technologist Schools
 
Primovist™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Primovist™ (U.S brand name Eovist®) is a highly specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans.
Primovist™ brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic scanning and imaging of the accumulation phase (best after 20 min.) can also be performed after bolus injection of Primovistâ„¢. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
Gadoxetic acid disodium, Gd-EOB-DTPA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Short T1-relaxation time
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
884 mosm/kgH2O
CONCENTRATION
0.25 mol/L
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
for sale
DISTRIBUTOR
See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Primovist™
for sale
spacer

• View the DATABASE results for 'Primovist™' (7).Open this link in a new window

 
Further Reading:
  Basics:
New MRI liver contrast agent Primovist® approved in EU
Thursday, 30 September 2004   by www.secinfo.com    
New MRI Liver Contrast Medium
Wednesday, 13 October 2004   by www.hospimedica.com    
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
  News & More:
Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests
Thursday, 18 November 2021   by www.nature.com    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents
Friday, 5 January 2018   by www.gov.uk    
MRI Resources 
Stimulator pool - Safety Products - Services and Supplies - MRI Reimbursement - MRI Training Courses - Implant and Prosthesis
 
     1 - 5 (of 6)     next
Result Pages : [1]  [2]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



MRI is trending to low field magnets :
reduced costs will lead to this change 
AI will close the gap to high field 
only in remote areas 
is only temporary 
never 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 29 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]